Grail, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 30,452 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the completion of the sale, the chief financial officer now owns 268,277 shares of the company’s stock, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Grail Trading Up 5.6 %
Shares of NASDAQ GRAL opened at $14.79 on Wednesday. Grail, Inc. has a 12-month low of $12.33 and a 12-month high of $23.36. The firm has a 50-day simple moving average of $13.84.
Analyst Ratings Changes
Several analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Grail in a report on Thursday, October 17th. They issued a “neutral” rating for the company. Wolfe Research started coverage on shares of Grail in a research note on Friday, November 15th. They set a “peer perform” rating on the stock.
About Grail
GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.
Featured Stories
- Five stocks we like better than Grail
- How to Choose Top Rated Stocks
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- How to Invest in Small Cap Stocks
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- CD Calculator: Certificate of Deposit Calculator
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
